RE:RE:RE:RE:More Insider BuyingHempdoc Wrote
bartlman wrote: Maybe it's just RW's way of saying "buy". If he can add 30k shares of a stock that he already owns lots of, it tells me that he is saying that right now the stock is a pretty safe buy. He wouldn't be buying if he didn't happen to have some insider knowledge suggesting that TLT is going onward and upward.
I agree, & believe it reveals not only his long term confidence in the technology, but also his short term confidence in the likelihood of an IND approval this quarter.
I believe we will also continue to hear news re: the onboarding of new trial sites & patients being enrolled or treated. However, as for the interim data, it's anybody's call. I'm mentally preparing for the possibility no one gets informed (including TLT) until the data either reaches statistical significance, or the study is stopped early due to stellar 1 yr efficacy results (i.e. >60%) in 20 to 25 patients, whichever occurs first....all in the name of scientific integrity. Hope TLT doesn't test our patience too much...would love to be a fly on the wall.
Shawn Shirazi, Ph.D., CEO – Drug Division, Theralase stated “Based on the high safety and the efficacy results demonstrated in the Phase Ib study, the TLD-1433 Anti-Cancer Technology (“ACT”) platform has the potential to be a viable treatment solution for NMIBC, if the Company is able to duplicate the efficacy results observed in the Phase Ib clinical study (67% CR) at an interim analysis of approximately 20 to 25 patients enrolled and treated, Theralase plans to meet with the FDA to review the results, with a focus on obtaining accelerated approval of the Companies ACT-PDT.
I recall looking in the last few months at his personal buys some of which were done under his children's names ... to me that sends a strong level of confidence ... what in your mind would you rather hear approval from shareholders or your children "" Dad your the greatest""